BerandaGLTO • NASDAQ
add
Galecto Inc
$3,36
Setelah Jam Perdagangan Normal:(4,76%)-0,16
$3,20
Tutup: 10 Jun, 18.05.19 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$3,29
Rentang hari
$3,26 - $3,45
Rentang tahun
$2,01 - $16,07
Kapitalisasi pasar
4,44 jt USD
Volume Rata-Rata
68,83 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | — | — |
Biaya operasional | 2,60 jt | -54,73% |
Laba bersih | -2,53 jt | 53,75% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -2,59 jt | 54,78% |
Tarif pajak efektif | -0,08% | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 11,94 jt | -56,06% |
Total aset | 15,36 jt | -52,69% |
Total liabilitas | 1,66 jt | -61,65% |
Total ekuitas | 13,71 jt | — |
Saham yang beredar | 1,32 jt | — |
Harga terhadap nilai buku | 0,35 | — |
Tingkat pengembalian aset | -39,99% | — |
Tingkat pengembalian modal | -43,77% | — |
Arus Kas
Perubahan kas bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -2,53 jt | 53,75% |
Kas dari operasi | -2,44 jt | 58,91% |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | -2,24 jt | -497,86% |
Arus kas bebas | -1,40 jt | 58,23% |
Tentang
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
5